Skip to main content
. 2019 Feb 21;7:52. doi: 10.1186/s40425-019-0528-x

Fig. 1.

Fig. 1

Clinical response to nivolumab and ipilimumab. a, Lung lesion before the treatment with anti-CTLA-4 and anti-PD-1 antibodies and after 8 weeks. There was a marked regression with 8 weeks of the treatement. b, After 16 weeks of treatment, a complete metabolic response was observed in the 18FDG-PET/CT scan